What Has Been the Progress and Growth of the Myelodysplastic Syndrome Drugs Market in Recent Years?
The myelodysplastic syndrome drugs market has seen considerable growth due to a variety of factors.
•Over the past few years, there has been a robust expansion in the market size of myelodysplastic syndrome drugs. It is anticipated to enhance from $2.25 billion in the year 2024 to approximately $2.47 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.8%.
Factors contributing to the growth in the historic period comprise the aging populace, progress in diagnostic technologies, cases of MDS related to chemotherapy, a rise in the number of cancer survivors, and advancements in clinical research and drug development.
What Can Be Expected from the Myelodysplastic Syndrome Drugs Market in the Coming Years?
The myelodysplastic syndrome drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market for drugs treating myelodysplastic syndrome is projected to experience robust growth in the coming years. The market value is anticipated to reach "$3.58 billion in 2029, growing at a compound annual growth rate (CAGR) of 9.7%.
Factors propelling this growth over the forecasted period include an increase in the geriatric population, advances in targeted therapies, better comprehension of disease processes, heightened awareness, early diagnosis, and growth in cancer research. Other influential trends observed during this period are optimized erythropoiesis-stimulating agents, combined therapies, an increased emphasis on iron chelation therapy, regulatory clearances and market reach, as well as patient-focused care approaches.
What Are The Leading Drivers Of Growth In The Myelodysplastic Syndrome Drugs Market?
The expected surge in myelodysplastic syndrome cases is projected to boost the expansion of the myelodysplastic syndrome drug market in the near future. Myelodysplastic syndrome, or MDS, encompasses a range of disorders marked by abnormal growth and development of blood cells in bone marrow. This kind of blood cancer disrupts the generation of healthy blood cells. The use of myelodysplastic syndrome drugs, which modulate or suppress the immune system reducing the need for red blood cell transfusions, allows for the treatment of MDS. As noted by the American Journal of Managed Care in October 2022, the estimate of MDS prevalence in the US is between 60,000 and 175,000 cases. Hence, the rising occurrence of myelodysplastic syndrome is galvanizing the myelodysplastic syndrome drug market's enhancement.
How Are The Segments Defined Within The Global Myelodysplastic Syndrome Drugs Market?
The myelodysplastic syndrome drugs market covered in this report is segmented –
1) By Therapeutic Class: Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics
2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts
3) By Route of Administration: Oral, Parenteral
4) By Applications: Original, Generics
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Immunomodulatory Drugs: Thalidomide, Lenalidomide, Pomalidomide
2) By Hypomethylating Agents: Azacitidine, Decitabine, Guadecitabine
3) By Anti-anemics: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion Products
Pre-Book The Myelodysplastic Syndrome Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Myelodysplastic Syndrome Drugs Market?
Leading corporations present in the myelodysplastic syndrome drugs market are focusing on the creation of telomerase inhibitors, with the objective of moderating the advancement of the disease by curbing the unrestricted division of anomalous cells. Telomerase inhibitors play a significant role in myelodysplastic syndrome medications as they work towards curbing the enzyme telomerase, thereby restraining the growth of abnormal cells, leading to potentially enhanced patient results. For example, in June 2024, Geron Corporation, a biotechnology organization based in the US, brought to market rytelo (imetelstat), an FDA-authorized intravenous telomerase inhibitor designed for adults suffering from low to intermediate-1 risk myelodysplastic syndromes (LR-MDS) and transfusion-dependent anemia that is resistant to and unfit for ESA. Providing durable transfusion self-sufficiency, improved hemoglobin levels, and catering to a previously unaddressed need in the myelodysplastic syndrome drugs market, Rytelo also flaunts a manageable safety profile.
Who Are the Key Players in the Myelodysplastic Syndrome Drugs Market?
Major companies operating in the myelodysplastic syndrome drugs market include:
• Amgen Inc.
• Celgene Corporation
• Otsuka Pharmaceutical Co. Ltd.
• Takeda Pharmaceutical Company Limited
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Lupin Ltd.
• Onconova Therapeutics Inc.
• Sun Pharmaceutical Industries Limited
• FibroGen Inc.
• Aprea Therapeutics
• Bayer AG
• Bristol Myers Squibb
• Celator Pharmaceuticals
• Crystal Genomics Inc.
• AbbVie Inc.
• Astex Pharmaceuticals Inc.
• Geron Co.
• Hikma Pharmaceuticals plc
• Jazz Pharmaceuticals Inc.
• Mylan NV
• Novartis AG
• Sandoz Inc.
• Syros Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Acceleron Pharma Inc.
• Agios Pharmaceuticals Inc.
• Incyte Corporation
• Array Biopharma Inc.
• MEI Pharma Inc.
What Is The Most Dominant Region In The Myelodysplastic Syndrome Drugs Market?
North America was the largest region in the Myelodysplastic syndrome drugs market in 2024.Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
